A particular alteration involves lysosomal dysfunction, which hinders the degradation of structurally damaged mitochondria, leading to cellular toxicity ( In AD, dysfunctional mitochondria accumulate and exacerbate lysosomal degradation bottlenecks
Insurance coverage varies for these medications, and even if your insurance does cover them, you may still need to pay a copay or coinsurance
One area where the clinic falls short is guarantees
Following enzyme induction, the extent of lobular involvement increases to include mid-lobular and sometimes periportal hepatocytes (Figure 1C and 1D)
Early preclinical data with other triple agonists, such as efocipegtrutide, further support their potential neuroprotective effect
Other Financial or Material Support/Honoraria: Novo Nordisk, GI Dynamics, AstraZeneca, Boehringer Ingelheim, Currax Pharmaceuticals Read and watch the full series on our website or on YouTube.